| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/15/2009 | CN100477986C Ascending-dose dosage form |
| 04/14/2009 | US7517996 methyl 3-(4-{4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-isoxazolyl}-benzylsulfanyl)propionate; compounds inhibit the physiological activity of lysophosphatidic acid (LPA); treatment of fibrosis of organs (liver, kidney, lung, and the like), hepatic disease |
| 04/14/2009 | US7517989 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 04/14/2009 | US7517987 Interleukin converting enzyme inhibitors such as 5-Fluoro-4-oxo-3-(2-(6-oxo-6H-pyrimidin-1-yl)-butyrylamino)-pentanoic acid, administered as modulators of cell apoptosis and inflammation |
| 04/14/2009 | US7517953 With low peroxide and anisidine values and high polyunsaturated fatty acid content; heating from 40 to 70 degrees C at a rate of 1 degree per minute, a plateau stage, cooling at the same rate; improved electrical efficency; baby formula |
| 04/14/2009 | US7517909 Using 3-amino-5-methyl-octanoic acid for therapy of psychiatric, pain and other disorders |
| 04/14/2009 | US7517898 2-tert-Butyl-N,N-diethyl-1-{[1-methylpiperidin-2-yl]methyl}-1H-benzimidazole-5-carboxamide; cannabinoid receptors agonists; analgesic, anticarcinogenic, antiinflammatory, anxiolytic agent; neurodegenerative diseases; gastrointestinal and cardiovascular disorders |
| 04/14/2009 | US7517892 Ligands for monoamine receptors and transporters, and methods of use thereof |
| 04/14/2009 | US7517881 Triazine derivatives, their preparation and therapeutic application thereof |
| 04/14/2009 | US7517879 Pyrrolidine derivatives as factor Xa inhibitors |
| 04/14/2009 | US7517874 Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain |
| 04/14/2009 | US7517871 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| 04/14/2009 | US7517686 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| 04/14/2009 | US7517672 Nucleic acids encoding mammalian T-type calcium channels |
| 04/14/2009 | US7517669 Increasing the intracellular amount of at least one ferritin-H or a derivative to an effective level for suppressing disease caused or enhanced by effects of intracellular iron mismanagement |
| 04/14/2009 | US7517661 Methods of screening for ligands for FPRL2 |
| 04/14/2009 | US7517658 Drug screening for human SNORF33 receptor agonist by contacting cells transfected with and expressing DNA encoding the human SNORF33 receptor, wherein cells prior to being transfected with the DNA do not express the human SNORF33 receptor; inflammation, infections, arthritis; autoimmune diseases |
| 04/14/2009 | US7517646 Provides functional molecule having an affinity and specificity to a target comparable to the affinity and specificity of an antibody against an antigen; modified oligonucleotide sequence |
| 04/14/2009 | US7517525 Methods of inhibiting amyloid toxicity |
| 04/14/2009 | US7517517 Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
| 04/14/2009 | CA2468658C [1,2,4]-triazole bicyclic adenosine a2a receptor antagonists |
| 04/14/2009 | CA2427817C Estrone-derivatives having cytoprotective activity |
| 04/14/2009 | CA2389111C Novel combination of loteprednol and .beta.2-adrenoceptor agonists |
| 04/14/2009 | CA2386190C Regulators of the hedgehog pathway, compositions and uses related thereto |
| 04/14/2009 | CA2359440C Phenylphenanthridines with pde-iv inhibiting activity |
| 04/14/2009 | CA2355341C The use of ara as a supplement for a lactating woman |
| 04/14/2009 | CA2348871C Multiparticulate modified release composition |
| 04/14/2009 | CA2337797C Naaladase inhibitors useful as pharmaceutical compounds and compositions |
| 04/14/2009 | CA2256007C Substituted heterocyclic benzocycloalkenes and their use as analgesic |
| 04/14/2009 | CA2237582C Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors |
| 04/14/2009 | CA2231244C Anti-stress agents for aquatic animals |
| 04/14/2009 | CA2138533C Drugs that enhance synaptic responses mediated by ampa receptors |
| 04/09/2009 | WO2009046453A2 Use of neuregulin-1 in reducing brain damage |
| 04/09/2009 | WO2009046299A2 Implantable drug depot for intrathecal drug delivery system for pain management |
| 04/09/2009 | WO2009046025A1 Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease |
| 04/09/2009 | WO2009046004A1 Carboxamide gabaa alpha2 modulators |
| 04/09/2009 | WO2009045519A1 Modulators of muscarinic receptors |
| 04/09/2009 | WO2009045497A1 Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| 04/09/2009 | WO2009045488A2 Novel crystalline forms of armodafinil and preparation thereof |
| 04/09/2009 | WO2009045314A1 Gamma secretase modulators |
| 04/09/2009 | WO2009045313A2 Oxypiperidine derivatives as histamine receptor antagonists |
| 04/09/2009 | WO2009044930A1 Pharmaceutical composition for inhibiting the accumulation of amyloid-β protein |
| 04/09/2009 | WO2009044788A1 Benzoxazinone derivative |
| 04/09/2009 | WO2009044555A1 Preparation and method of administering vaccine and iontophoresis device using the preparation |
| 04/09/2009 | WO2009044554A1 Preparation and method of administering vaccine and iontophoresis device using the preparation |
| 04/09/2009 | WO2009044547A1 Nerve cell death inhibitor |
| 04/09/2009 | WO2009044211A1 Process for the preparation of zolmitriptan, salts and solvates thereof |
| 04/09/2009 | WO2009044202A1 Compounds and methods for pharmaceutical use |
| 04/09/2009 | WO2009044160A1 Pyridine derivatives for the treatment of amyloid-related diseases |
| 04/09/2009 | WO2009044127A1 Therapeutic use of diaminophenothiazines |
| 04/09/2009 | WO2009044019A2 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof |
| 04/09/2009 | WO2009044018A2 Derivatives of 1-oxo-1,2-dihydroisoquinoline-5-carboxamides and of 4-oxo-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics |
| 04/09/2009 | WO2009044007A2 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamide derivatives, preparation and therapeutic use thereof |
| 04/09/2009 | WO2009043922A2 Extracellular targets for alzheimer's disease |
| 04/09/2009 | WO2009043884A1 Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors |
| 04/09/2009 | WO2009043883A1 Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors |
| 04/09/2009 | WO2009043856A2 Modulation of tissue fatty acid composition of a host by human gut bacteria |
| 04/09/2009 | WO2009043834A1 Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound |
| 04/09/2009 | WO2009043797A2 Salts of a cgrp antagonist, method for producing the same and use thereof as drugs |
| 04/09/2009 | WO2009043784A1 Cyclopropyl aryl amide derivatives and uses thereof |
| 04/09/2009 | WO2009043780A1 Tetrazole-substituted aryl amide derivatives and uses thereof |
| 04/09/2009 | WO2009043593A1 Combination therapy using memantine and glitazones |
| 04/09/2009 | WO2009043529A1 Thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | WO2009043528A1 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | WO2009043527A2 Therapeutic use of human growth hormone 1-43 |
| 04/09/2009 | WO2009043526A2 Use of gip ( 6-30) alone or in combination with hgh as a therapeutic agent |
| 04/09/2009 | WO2009043525A2 Use of the combination of gluten exorphin c and cd36 as a therapeutic agent |
| 04/09/2009 | WO2009043524A2 Use of a peptide as therapeutic agent |
| 04/09/2009 | WO2009043523A2 Cortistatin 17 and neuropeptide 1 for use as therapeutic agent |
| 04/09/2009 | WO2009043522A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043521A2 Use of urocortin iii and urocortin i as therapeutic agents |
| 04/09/2009 | WO2009043520A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | WO2009043519A2 Use of band 3 protein and pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043518A2 Use of a combination of cart peptides as a therapeutic agent |
| 04/09/2009 | WO2009043507A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043506A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043505A2 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer |
| 04/09/2009 | WO2009043504A2 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer |
| 04/09/2009 | WO2009043481A2 Use of adrenomedullin 13-52 and optionally retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043480A2 Use of leptin (22-56 ) as a therapeutic agent |
| 04/09/2009 | WO2009043479A2 Use of eaa-mart1 (26-35) for the treatment of human cytomegalovirus infections |
| 04/09/2009 | WO2009043478A2 Use of bubuc and optionally eaa-mart1 (26-35) as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043477A2 Use of glpl (7-36) alone or in combination with leptin 22-56 as a therapeutic agent |
| 04/09/2009 | WO2009043476A2 Neuromedin s as a therapeutic agent |
| 04/09/2009 | WO2009043469A2 Use of pneumadin as a therapeutic agent |
| 04/09/2009 | WO2009043468A2 Use of corticotropin-releasing factor as a therapeutic agent |
| 04/09/2009 | WO2009043467A1 U e of urocortin and corticotropin-releasing fact r as therapeutic agents |
| 04/09/2009 | WO2009043466A2 Therapeutic use of the peptide gluten exorphin a5 |
| 04/09/2009 | WO2009043465A2 Use of beta-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043464A2 Astressin and beta- endorphin for use as therapeutic agents |
| 04/09/2009 | WO2009043463A2 Use of gluten exorphin c : as a therapeutic agent |
| 04/09/2009 | WO2009043462A1 Use of neuropeptide af as a therapeutic agent |
| 04/09/2009 | WO2009043461A1 Use of a hnp-1 defensin peptide, alone or in combination with neuropeptide af, as a therapeutic agent |
| 04/09/2009 | WO2009043460A1 Use of alpha-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043459A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | WO2009043458A2 Use of oxytocin to treat many diseases |
| 04/09/2009 | WO2009043457A2 Use of human hemokinin-1 and optionally oxytocin to treat diseases involving excessive angiogenesis |
| 04/09/2009 | WO2009043456A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043455A2 Therapeutic uses of angiogenin 108-122 and gluten exorphin a5 |
| 04/09/2009 | WO2009043454A2 Use of pacap-27 as a therapeutic agent |